HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211

Clinical Infectious Diseases

Volumn 44, Issue 4, 2007, Pages 591-595

  Wilkin, Timothy J ^a,l   Su, Zhaohui ^b   Kuritzkes, Daniel R ^c   Hughes, Michael ^b   Flexner, Charles ^e   Gross, Robert ^g   Coakley, Eoin ^h   Greaves, Wayne ⁱ   Godfrey, Catherine ^f   Skolnik, Paul R ^d   Timpone, Joseph ^j   Rodriguez, Benigno ^k   Gulick, Roy M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h MONOGRAM BIOSCIENCES   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VICRIVIROC; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SCREENING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANALYSIS OF VARIANCE; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD4; CLINICAL TRIALS; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT SELECTION; PROBABILITY; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL LOAD;

EID: 33846932573     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511035     Document Type: Article

References (16)

1. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100:10598-602.
2. + cell depletion and progression to AIDS. Ann Int Med 1993; 118:681-8.
3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
4. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-74.
5. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.
6. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis 2005; 18:9-15.
7. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-2.
8. Schurmann D, Rouzier R, Nougarede R, et al. SCH D: Antiviral activity of a CCR5 receptor antagonist [abstract 140-LB]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
9. Wolinsky SM, Veazey RS, Kunstman KJ, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004; 328:19-29.
10. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H-1136]. In: Program and abstracts of the 44th International Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
11. Melby T, DeSpirito M, DeMasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006; 194:238-46
12. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
13. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
14. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926-30.
15. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382-92.
16. Eckstein DA, Penn ML, Korin YD, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001; 15:671-82.